Restricted accessResearch articleFirst published online 2016-1-14
Protective effects of 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors on oxidative modification of human low density lipoproteins in vitro
It has been suggested that 2,3-diaryl-substituted indole-based cyclooxygenase-2 (COX-2) inhibitors (2,3-diaryl-indole coxibs) do not only appear as potent anti-inflammatory agents but also show the ability to scavenge reactive oxygen species (ROS). This led to the hypothesis that 2,3-diaryl-indole coxibs also may act as potent inhibitors of oxidative modification of low-density lipoprotein (LDL), which is considered a key factor in atherogenesis. The aim of this study was to explore i) the reactivity of a series of new synthesized 2,3-diaryl-indoles with several well characterized LDL oxidation systems and ii) subsequent effects on an inflammatory/atherogenic microenvironment. The results demonstrate that under the present experimental conditions2,3-diaryl-indoles showed potent ROS scavenging activity and were able to markedly inhibit LDL oxidation. Subsequently, this led to a substantial decrease of modified LDL uptake by scavenger receptors in THP-1 macrophages in vitro and in rats in vivo. Moreover, modified LDL-mediated monocyte/neutrophil adhesion to endothelial cells, macrophage NFκB activation, as well as macrophage and endothelial cell cytokine release was diminished in vitro. The reduction of modified LDL-induced atherogenic effects by antioxidant 2,3-diaryl-indole coxibs may widen the therapeutic window of COX-2 targeted treatment.
AntosiewiczJ., DamianiE., JassemW., WozniakM., OrenaM. and GreciL., Influence of structure on the antioxidant activity of indolinic nitroxide radicals, Free Radicals in Biology & Medicine22 (1997), 249–255.
2.
Bonnefont-RousselotD., ChevéG., GozzoA., TailleuxA., GuillozV., CaiseyS., TeissierE., FruchartJ.C., DelattreJ., JoreD., LesieurD., DuriezP. and Gardès-AlbertM., Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation, Journal of Pineal Research33 (2002), 109–117.
3.
BoudjeltiaK.Z., LegssyerI., Van AntwerpenP.
, KisokaR.L.,
BabarS.,
MoguilevskyN.,
DelreeP.,
DucobuJ.,
RemacleC.,
VanhaeverbeekM.
and BroheeD.,
Triggering of inflammatory response by myeloperoxidase-oxidized LDL, Biochemistry and Cell Biology84 (2006), 805–812.
4.
CamíG.E., Chacón VillalbaM.E., ColinasP.,
EcheverríaG.A.,
EstiuG.
and SoriaD.B.,
Crystal structure, spectroscopy and theoretical studies of p-cyanobenzenesulfonamide and a Cu(II) complex, Journal of Molecular Structure1024 (2012), 110–116.
5.
CampbellJ.A., BordunovV., BrokaC.A., BrownerM.F., KressJ.M., MirzadeganT., RameshaC., SanpabloB.F., StablerR., TakaharaP., VillasenorA., WalkerK.A., WangJ.H., WelchM. and WellerP., Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors, Bioorganic Medicinal Chemistry Letters14 (2004), 4741–4745.
6.
CapraV., BäckM., BarbieriS.S., CameraM., TremoliE. and RovatiG.E., Eicosanoids and their drugs in cardiovascular diseases: Focus on atherosclerosis and stroke, Medicinal Research Reviews33 (2013), 364–438.
7.
CipolloneF., CicoliniG. and BucciM., Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives, Pharmacology & Therapeutics118 (2008), 161–180.
8.
CominaciniL., GarbinU., PasiniA.F., DavoliA., CampagnolaM., PastorinoA.M., GaviraghiG. and LoV., Cascio, Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: Inhibitory effect of lacidipine, Journal of Hypertension16 (1998), 1913–1919.
9.
CostaD., MoutinhoL., LimaJ.L.F.C. and FernandesE., Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs, Biological and Pharmaceutical Bulletin29 (2006), 1659–1670.
10.
CostaS., ZimettiF., PedrelliM., CremonesiG. and BerniniF., Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages, Pharmacological Research62 (2010), 265–270.
11.
CrisafulliC., GaluppoM. and CuzzocreaS., Effects of genetic and pharmacological inhibition of TNF-alpha in the regulation of inflammation in macrophages, Pharmacological Research60 (2009), 332–340.
12.
EldorA., FuksZ., MatznerY., WitteL.D. and VlodavskyI., Perturbation of endothelial functions by ionizing irradiation: Effects on prostaglandins, chemoattractants and mitogens, Seminars in Thrombosis and Hemostasis15 (1989), 215–225.
13.
ErlW., WeberP.C. and WeberC., Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands, Atherosclerosis136 (1998), 297–303.
14.
EsterbauerH., StrieglG., PuhlH. and RothenederM., Continuous monitoring of in vitro oxidation of human low density lipoprotein, Free Radical Research Communications6 (1989), 67–75.
15.
GozzoA., LesieurD., DuriezP., FruchartJ.C. and TeissierE., Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model, Free Radicals in Biology & Medicine26 (1999), 1538–1543.
16.
Haase-KohnC., WolfS., LenkJ. and PietzschJ., Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells, Biochemical and Biophysical Research Communications413 (2011), 494–498.
17.
HalliwellB., GutteridgeJ.M. and AruomaO.I., The deoxyribose method: A simple test-tube assay for determination of rate constants for reactions of hydroxyl radicals, Analytical Biochemistry165 (1987), 215–219.
18.
HarirforooshS., AsgharW. and JamaliF., Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications, Journal of Pharmacy & Pharmaceutical Sciences16 (2013), 821–847.
19.
HoppmannS., SteinigerB., StrobelK., HaaseC. and PietzschJ.In vivo catabolism of hypochlorite-modified low density lipoproteins (LDL): Insights from small animal positron emission tomography studiesstudies, In:
PietzschJ.,
(ed.), Research
Signpost, Trivandrum, India, 2006, pp 197–219
20.
HuW., GuoZ., ChuF., BaiA., YiX., ChengG. and LiJ., Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: A new series of selective COX-2 inhibitors, Bioorganic Medicinal Chemistry11 (2003), 1153–1160.
21.
ImJ.Y. and KimD.,
PaikS. G.,
and HanP. L.,
Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation, Free Radical Biology and Medicine41 (2006), 960–972.
22.
Jawabrah Al-HouraniB.,
SharmaS.K.,
SureshM.,
and
WuestF., Cyclooxygenase-2 inhibitors: A literature and patent review -, Expert Opinion on Therapeutic Patents21(9) (2011), 1339–1432.
23.
KaminskaiaN.V., UllmannG.M., FultonD.B. and KosticN.M., Spectroscopic, kinetic, and mechanistic study of a new mode of coordination of indole derivatives to platinum(II) and palladium(II) ions in complexes, Inorganic Chemistry39 (2000), 5004–5013.
24.
KarekalM.R., Biradar V.,
and
Bennikallu Hire MathadaM.Synthesis, characterization, antimicrobial, DNA cleavage, and antioxidant studies of some metal complexes derived from schiff base containing indole and quinoline moieties, Bioinorganic Chemistry and Applications2013 (2013), 315972.
25.
KniessT., LaubeM., BergmannR., SehnF., GrafF., SteinbachJ., WuestF. and PietzschJ., Radiosynthesis of a 18F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro
and in vivo, Bioorganic Medicinal Chemistry20 (2012), 3410–3421.
26.
KoppraschS., LeonhardtW., PietzschJ. and KühneH., Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells, Atherosclerosis136 (1998), 315–324.
27.
KoppraschS., PietzschJ. and GrässlerJ., The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL, Molecular and Cellular Biochemistry258 (2004), 121–127.
28.
KoppraschS., PietzschJ. and WestendorfT., H-J Kruse and J. Grässler, The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells, The International Journal of Biochemistry & Cell Biology36 (2004), 460–471.
29.
KoppraschS., RichterK., LeonhardtW., PietzschJ. and GrässlerJ., Urate attenuates oxidation of native low-density lipoprotein by hypochlorite and the subsequent lipoprotein-induced respiratory burst activities of polymorphonuclear leukocytes, Molecular and Cellular Biochemistry206 (2000), 51–56.
30.
KrukI., Aboul-EneinH.Y., MichalskaT., LichszteldK., Kubasik-KladnaK. and OlgenS., scavenging activity for reactive oxygen species by N-substituted indole-2-carboxylic acid esters, Luminescence22 (2007), 379–386.
31.
LapennaD., CiofaniG., FestiD., NeriM., PierdomenicoS.D., GiamberardinoM.A. and CuccurulloF., Antioxidant properties of ursodeoxycholic acid, Biochemical Pharmacology64(11) (2002), 1661–1667.
32.
LaubeM., KniessT. and PietzschJ., Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity–a critical update, Molecules18 (2013), 6311–6355.
33.
LaubeM., TonderaC., SharmaS.K. and BechmannN., F-J Pietzsch, A. Pigorsch, M. Köckerling, F. Wuest, J. Pietzsch and T. Kniess, 2,3-Diaryl-substituted indole based COX-2 inhibitors as leads for imaging tracer development, RSC Advances4 (2014), 38726–38742.
34.
LussiD., PotapovichA., RiccardoM., DellambraE., PressiG., KostyukV., Dal TosoR.,
De LucaC.,
PastoreS.,
and Korkina L., Anti-inflammatory effects of concentrated ethanol extracts of Edelweiss (Leontopodium alpinum Cass.) callus cultures towards human keratinocytes and endothelial cells, Mediators of Inflammation2012 (2012), 498373.
35.
MarnettL.J., The COXIB experience: A look in the rearview mirror, Annual Review of Pharmacology and Toxicology49 (2009), 265–290.
36.
MazièreC. and MazièreJ.C., Activation of transcription factors and gene expression by oxidized low-density lipoprotein, Free Radicals in Biology & Medicine46 (2009), 127–137.
37.
MukherjeeD., NissenS.E. and TopolE.J., Risk of cardiovascular events associated with selective COX-2 inhibitors, Journal oft the American Medical Association286 (2001), 954–959.
38.
OguoghoA., KritzH., WagnerO. and SinzingerH., 6-oxo-PGF1α and 8-epi-PGF2α in the arterial wall layers of various species: A comparison between intact and atherosclerotic areas, Prostaglandins, Leukotrienes & Essential Fatty Acids64 (2001), 167–171.
39.
PenningT.D., TalleyJ.J., BertenshawS.R., CarterJ.S., CollinsP.W., DocterS., GranetoM.J., LeeL.F., MalechaJ.W., MiyashiroJ.M., RogersR.S., RogierD.J., YuS.S., AndersonG.D., BurtonE.G., CogburnJ.N., GregoryS.A., KoboldtC.M., PerkinsW.E., SeibertK., VeenhuizenA.W., ZhangY.Y. and IsaksonP.C., Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-5, celecoxib), Journal of Medicinal Chemistry40 (1997), 1347–1365.
40.
PietzschJ., Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of iron-mediated oxidation of proline and arginine side-chain residues of low-density lipoprotein apolipoprotein B-100, Biochemical and Biophysical Research Communications270 (2000), 852–857.
41.
PietzschJ., BergmannR., RodeK., HultschC., PawelkeB., WuestF. and van den HoffJ., Fluorine-18 radiolabeling of low density lipoproteins (LDL): A potential approach for characterization and differentiation of metabolism of native and oxidized LDL in vivo, Nuclear Medicine and Biology31 (2004), 1043–1050.
42.
PietzschJ., BergmannR., WuestF., PawelkeB., HultschC. and van den HoffJ., Catabolism of native and oxidized low density lipoproteins: In vivo insights from small animal positron emission tomography studies, Amino Acids29 (2005), 389–404.
43.
PietzschJ., KoppraschJ.S.,
and
BergmannR.,Analysis of 3-chlorotyrosine as a specific marker of protein oxidation: The use of N(O,S)-ethoxycarbonyltrifluoroethyl ester derivatives and gas chromatography/mass spectrometry, Rapid Communications in Mass Spectrometry17 (2003), 767–770.
44.
PietzschJ., LaubeM., PietzschF.J., BergmannR. and KniessT., Concomitant targeting of cyclooxygenase-2 and oxidant stress pathways for radioprotection of endothelial cells, In:
LewisB.S.,
FlugelmanM.Y.,
and HalonD.A., (eds.), Medimond S.r.l - Monduzzi Editore International, Bologna, Italy, 2011, pp. 107–110.
45.
PraticòD., Prostanoid and isoprostanoid pathways in atherogenesis, Atherosclerosis201 (2008), 8–16.
46.
PraticòD., LawsonJ.A., RokachJ. and FitzGeraldG.A., The isoprostanes in biology and medicine, Trends in Endocrinology & Metabolism12 (2001), 243–247.
47.
ReisE.D., RoqueM., DanskyH., FallonJ.T., BadimonJ.J., Cordon-CardoC., ShiffS.J. and FisherE.A., Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice, Proceedings of the National Academy of Sciences USA97 (2000), 12764–12769.
48.
RobbesynF., SalvayreR. and Negre-SalvayreA., Dual role of oxidized LDL on the NF-kappaB signaling pathway, Free Radical Research38 (2004), 541–551.
49.
SeegerH., MueckA.O. and LippertT.H., Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein, British Journal of Clinical Pharmacology44 (1997), 283–284.
50.
SimmonsD.L., BottingR.M. and HlaT., Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition, Pharmacological Reviews56 (2004), 387–437.
51.
SteffenY., ScheweT. and SiesH., Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase, Biochemical and Biophysical Research Communications331 (2005), 1277–1283.
52.
SteinbergD., ParthasarathyS., CarewT.E., KhooJ.C. and WitztumJ.L., Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, The New England Journal of Medicine320 (1989), 915–924.
53.
SuzenS., BozkayaP., CobanT. and NebioğluD., Investigation of the in vitro antioxidant behaviour of some 2-phenylindole derivatives: Discussion on possible antioxidant mechanisms and comparison with melatonin, Journal of Enzyme Inhibition and Medicinal Chemistry21 (2006), 4405–4411.
54.
TerkeltaubR., BankaC.L., SolanJ., SantoroD., BrandK. and CurtissL.K., Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity, Arteriosclerosis and Thrombosis14 (1994), 47–53.
55.
UllmS., LaubeM., BechmannN., KniessT. and PietzschJ., Organotypical vascular model for characterization of radioprotective compounds: Studies on antioxidant 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors, Clinical Hemorheology and Microcirculation58 (2014), 281–295.
56.
UllmS., SehnF., LaubeM., TonderaC., BechmannN., MoschB., KniessT. and PietzschJ., Targeting cyclooxygenase-2 and oxidant stress pathways for attenuation of radiation-induced vascular dysfunctionIn:
ZarzueloA., and
JimenezR., (eds.), Medimond S.r.l - Monduzzi Editore International, Bologna, Italy, 2013, pp. 8790.
57.
VaporciyanA.A., JonesM.L. and WardP.A., Rapid analysis of leukocyte-endothelial adhesion, Journal of Immunological Methods159 (1993), 93–100.
58.
WalterM.F., JacobR.F., DayC.A., DahlborgR., WengY. and MasonR.P., Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs, Atherosclerosis177 (2004), 235–243.
59.
Walters-LaporteE., FurmanC., FouquetS., Martin-NizardF., LestavelS., GozzoA., LesieurD., FruchartJ.C., DuriezP. and TeissierE., A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells, Journal of Cardiovascular Pharmacology32 (1998), 582–592.
60.
WasanK.M., BrocksD.R., LeeS.D., Sachs-BarrableK. and ThorntonS.J., Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery, Nature Reviews Drug Discovery7 (2008), 84–99.
61.
YouY., WangJ., TongY., HaoQ., LiY., YangH., HuangL. and LiaoF., Anti-inflammatory effect of acetylharpagide demonstrated by its influence on leukocyte adhesion and transmigration in endothelial cells under controlled shear stress, Clinical Hemorheology and Microcirculation56 (2014), 205–217.
62.
ZhangC., The role of inflammatory cytokines in endothelial dysfunction, Basic Research in Cardiology103 (2008), 398–406.
